Altimmune, Inc.

ALT · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.4%

Institutions77.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$41000	$20000	$426000	-$68000	$4.41M	$8.19M	$5.80M	$10.33M	$10.74M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$94.49M	-$103.17M	-$95.93M	-$87.74M	-$96.91M	-$54.80M	-$21.46M	-$42.83M	-$52.05M	-$11.26M
Operating income as a percentage of revenue.	-230461.0%	-515860.0%	-22518.5%	129029.4%	-2197.4%	-669.5%	-370.0%	-414.6%	-484.7%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$88.09M	-$95.06M	-$88.45M	-$84.71M	-$97.09M	-$49.04M	-$20.52M	-$39.17M	-$51.36M	$193.85M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.00	$-1.00	$-1.00	$-1.00	$-2.35	$-1.91	$-1.00	$-15.16	$-4.00	$2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-1.00	$-1.00	$-1.00	$-2.35	–	–	–	–	$2.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$43.76M	$36.93M	$135.12M	$111.10M	$190.30M	$115.92M	$8.96M	$33.72M	$8.77M	$153.99M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$279.93M	$139.31M	$210.64M	$206.93M	$218.86M	$245.12M	$54.06M	–	$63.03M	$224.74M
All of the company's interest-bearing borrowings, short and long term combined.	$34.29M	–	–	$4.58M	$1.45M	$1.83M	$1.86M	$1.92M	$4.62M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$55.04M	$15.80M	$16.54M	$21.64M	$19.73M	$19.24M	$8.54M	–	$14.35M	$205.28M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$224.89M	$123.51M	$194.10M	$185.29M	$199.13M	$225.88M	$45.52M	–	$39.40M	$19.46M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$67.53M	-$79.85M	-$75.81M	-$62.59M	-$78.24M	-$34.44M	-$9.60M	-$9.39M	-$20.21M	$201.51M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$11000	–	$47000	$126000	$12.12M	$203957	$1227	$975407	$112441	$30687
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$67.55M	–	-$75.86M	-$62.71M	-$90.36M	-$34.64M	-$9.60M	-$10.36M	-$20.33M	$201.48M

	You	Peer avg
Revenue Growth	–	+3.5%
ROE	-28.9%	-119.8%

Altimmune, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison